| 1 |
35203369 | Selective PPARĪ± Modulator Pemafibrate and Sodium-Glucose Cotransporter 2 Inhibitor Tofogliflozin Combination Treatment Improved Histopathology in Experimental Mice Model of Non-Alcoholic Steatohepatitis. | 2022 Feb 18 |
2 |
| 2 |
34029949 | The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. | 2021 Aug |
2 |
| 3 |
33098615 | The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice. | 2020 Dec |
2 |
| 4 |
30682139 | Influence of long term administration of tofogliflozin on chronic inflammation of visceral adipose tissue in mice with obesity induced by a high-fat diet. | 2019 |
1 |
| 5 |
31638239 | Suppressive effects of the sodiumāglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice. | 2019 Dec |
2 |
| 6 |
28928093 | Effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on weight loss is partly mediated by liver-brain-adipose neurocircuitry. | 2017 Nov 4 |
2 |
| 7 |
28938561 | Preventive effects of the sodium glucose cotransporter 2 inhibitor tofogliflozin on diethylnitrosamine-induced liver tumorigenesis in obese and diabetic mice. | 2017 Aug 29 |
1 |
| 8 |
27407083 | Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. | 2016 Nov |
2 |
| 9 |
25000147 | Tofogliflozin, a sodium/glucose cotransporter 2 inhibitor, attenuates body weight gain and fat accumulation in diabetic and obese animal models. | 2014 Jul 7 |
1 |
| 10 |
23751087 | Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. | 2013 Oct |
1 |
| 11 |
22410641 | Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. | 2012 Jun |
1 |